The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
NeoHx study: Perioperative treatment with trastuzumab in combination with capecitabine and oxaliplatin (XELOX-T) in patients with HER2 resectable stomach or esophagogastric junction (EGJ) adenocarcinoma—R0 resection, pCR, and toxicity analysis.
Fernando Rivera
Consultant or Advisory Role - Roche
Research Funding - Bayer; Roche
Paula Jiménez
No relevant relationships to disclose
Pilar Garcia Alfonso
No relevant relationships to disclose
Carlos Lopez
No relevant relationships to disclose
Javier Gallego
No relevant relationships to disclose
M. Luisa Limon
No relevant relationships to disclose
Maria Alsina
No relevant relationships to disclose
Luis Lopez-Gomez
No relevant relationships to disclose
Maica Galán
No relevant relationships to disclose
Esther Falco
No relevant relationships to disclose
Jose Luis Manzano
No relevant relationships to disclose
Encarnación González
No relevant relationships to disclose
Raquel Serrano
No relevant relationships to disclose
Eva Fernandez Parra
No relevant relationships to disclose
Monica Jorge
No relevant relationships to disclose